secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quoin Pharmaceuticals, Ltd. (QNRX)
CIK:        0001671502
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-109802
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quoin achieves 4% and 5% rapamycin loadings in topical and patch; clinical testing planned H1 2026
--------------------------------------------------------------------------------

- Rapamycin loading 4% w/w in proprietary topical formulation; 5% w/w in dermal patch system.
- Clinical trial and stability batch manufacture to start Q4 2025; clinical testing in H1 2026.
- Initial targets: Microcystic Lymphatic Malformations and Venous Malformations (no FDA-approved treatments).
- CEO notes capital raise completed to fund Netherton Syndrome pivotal studies and advance rapamycin programs.
- Milestone complements ongoing late-stage Netherton Syndrome and Peeling Skin Syndrome development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925109802/0001104659-25-109802-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671502/000110465925109802/tm2530990d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-109802

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer